The acquisition will involve the purchase of stock and mandatory convertible preferred shares through secondary transactions.
Possible sales might value UTAC at around $3 billion.
Its clinical itinerary racked up 95% on the “completely certified” standards.
Since March 2025, Everlasting’s international equity was 44.36%, below 47.30% in December 2024.
This toll suspension does not put on China, which will certainly deal with a 125% toll.
Sign in to your account